Continue to Site

Drug Discovery and Development

The most innovative pharmaceutical agents of 2020

By |

adhansiaxrAdhansia XR

Adlon Therapeutics, a subsidiary of Purdue Pharma

Adlon Therapeutics’s Adhansia XR is a central nervous system stimulant that is used for the treatment of attention deficit hyperactivity disorder (ADHD) in people ages 6 and older.

Common adverse reactions associated with taking Adhansia XR in adults are insomnia, dry mouth and decreased appetite. Common adverse reactions in pediatric patients include decreased appetite, insomnia and weight decreased.

Next >>

Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tagged With: , , , , , , , , , , , , , , , , , , , , , , , ,
 

About The Author

Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at [email protected].

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development